x min read

Equities in Focus - Ford Motor Company (NYSE:F), 21Vianet Group Inc (NASDAQ:VNET), Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA)

Equities in Focus - Ford Motor Company (NYSE:F), 21Vianet Group Inc (NASDAQ:VNET), Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA)
Written by
Joel Najarian
Published on
October 10, 2014
Copy URL
Share on LinkedIn
Share on Reddit
Share on Twitter/X
Share on Facebook
InsidrFinancial

Ford Motor Company (NYSE:F), the auto maker posted a 0.2% decrease in September sales in China, hurt by a 4% drop in passenger-car sales for the month compared with a year earlier. Ford Motor Company (NYSE:F) is trading within a 52-week range of $13.62 to $18.12. The company said while its sales in China for the first three quarters of the year were up 26% from the year-earlier period to 813,412 units, its September sales in China slipped to 95,875 vehicles, below last year's 96,111 vehicles. Weighing on the auto maker's overall China sales for the month, Ford's passenger-car joint venture in China, Changan Ford, posted a 4% drop in September to 69,061 units.21Vianet Group Inc (NASDAQ:VNET), the Chinese Internet data center services provides said it forged a strategic joint venture with Foxconn Technology. 21Vianet Group Inc (NASDAQ:VNET) and Foxconn will invest a total of $25 million in the joint venture and each company will own 60% and 40%, respectively. The two companies will jointly build and develop a global supply chain for Internet data center and cloud computing infrastructure markets. In addition, 21Vianet and Foxconn will open an Internet infrastructure and engineering technology research and development center.Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) said that the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) has concluded its review of Iclusig (ponatinib) under the Article 20 referral procedure and has recommended that Iclusig continue to be used in Europe in accordance with its already approved indications. Shares Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), the global oncology company are up 4.59% at $5.70, with a 52-week range of $2.15 - $9.83.The PRAC is the committee at the EMA that is responsible for assessing and monitoring safety issues for human medicines. The PRAC's recommendations are considered by the CHMP when it adopts opinions for centrally authorized medicines and referral procedures. The indications authorized by the committee for Iclusig include the treatment of adult patients with chronic phase, accelerated phase or blast phase chronic myeloid leukaemia (CML) who are resistant to dasatinib or nilotinib, who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation; and the treatment of adult patients with Philadelphia-chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate, or who have the T315I mutation.

Discover Hidden Gems

Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.